FPA-150 is under clinical development by Five Prime Therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FPA-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FPA-150 is under development for the treatment of advanced or metastatic breast, triple negative breast cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and endometrial cancer. The drug candidate is a monoclonal antibody acts by targeting B7-H4.
It was also under development for the treatment of bladder cancer.
Five Prime Therapeutics overview
Five Prime Therapeutics (Five Prime), a subsidiary of Amgen Inc, is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company’s pipeline products include cabiralizumab; Bemarituzumab (FPA144); FPT155; FPA157; and BMS-986258. Five Prime has also developed proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein therapeutics. The company has development collaborations with various companies to advance its pipeline products. Five Prime is headquartered in South San Francisco, California, the US.
For a complete picture of FPA-150’s drug-specific PTSR and LoA scores, buy the report here.